Navigation Links
Following a Good Start to the Year Shire Reaffirms Full Year 2008 Financial Guidance
Date:4/25/2008

arable financial measures prepared in accordance with US GAAP, see pages 24-25.

2008 Outlook

R&D pipeline and new product launches in the next two years

Subject to obtaining relevant regulatory/governmental approvals, the following product launches are planned over the next two years:
- MEZAVANT in the EU during 2008;

- VYVANSE for use in adult patients in the US in Q2 2008;

- DAYTRANA in the EU during H1 2009;

- INTUNIV in the US during H2 2009; and - FOSRENOL in the pre-dialysis Chronic Kidney Disease ("CKD") market in the US during 2009.

2008 Financial Outlook

We reaffirm the previous guidance given as part of the 2007 year-end results as follows:

We expect 2008 total revenue growth to be in the mid to high teens range. Based on existing prescription trends and the recently received approval for the adult indication, we currently expect VYVANSE sales to be at the lower end of the previously stated range of $350 to $400 million.

Costs are estimated as follows:

- Phase 3(b) and Phase 4 studies to support existing launches in the Specialty Pharmaceuticals ("Specialty") business and new product development in both the Specialty and HGT businesses will result in R&D spend for 2008 in the range of $465 to $490 million;

- Existing and planned launches will require additional advertising and promotional spend resulting in Selling, General & Administration ("SG&A") costs for 2008 in the range of $1,125 to $1,165 million;

- Business expansion including new and enlarged manufacturing and research facilities for HGT, the enlargement of other facilities and the global roll out of new and upgraded IT infrastructures, will see a significant cash investment in capital projects in 2008 in the range of $320 to $350 million (2007: $110 million);

- Due to the higher capital expenditure, the depreciation charge for 2008 is expected to increase by approximately 50% compared to
'/>"/>

SOURCE Shire plc
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
2. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
3. Rosetta Genomics Announces Initiation of In Vivo Studies Following Successful Completion of First Milestone in MicroRNA-based Therapeutic Program for Liver Cancer
4. Sigma-Aldrich Achieves Double Accreditation as a Certified Reference Material Producer Following ISO/IEC 17025 and ISO Guide 34
5. In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement:
6. Velcura Therapeutics, Inc. Can Begin Clinical Trials Following Successful Investigational New Drug Application to U.S. FDA
7. Cardiums Corgentin Preclinical Program Shows High Levels of Targeting to Acutely Ischemic Heart Muscle Following Intracoronary Infusion
8. Nereus Pharmaceuticals Initiates Clinical Trial of NPI-2358 in Non-Small Cell Lung Cancer Following Encouraging Phase 1 Data
9. ITSSD: Russia Can Secure Greatest Biotech Market Advances Following US, Not EU Innovation Model
10. Optherion, Inc. Completes $37 Million Start Up Financing
11. Actress Aida Turturro Tells Americans to Start Now to Talk With Their Healthcare Provider About Taking Control of Their Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... the Nanyang Technological University (NTU) signed the Memorandum ... for Scientific Research (CNRS) and the Thales Group ... laboratory, the three parties are meeting again in ... Laboratory at NTU. , Located at the ... harness the latest in science and technology to ...
(Date:12/16/2009)... Hahnemann among the Best in the Nation ... Hospital proudly announces it has been granted Magnet(R) ... Magnet Recognition Program(R). Magnet(R) is one of the ... center can achieve, and places Hahnemann among the ... have achieved this prestigious distinction. ,, At 9:00 ...
(Date:12/16/2009)... INDIANAPOLIS, Dec. 16 /PRNewswire/ -- ... Indiana,s life sciences industry and an active venture ... Company, Indiana State Teachers Retirement Fund, Indiana University, ... M. Fairbanks Foundation, and Credit Suisse today announced ... million venture capital fund of funds. ,, Organized ...
(Date:12/16/2009)... Sequenom, Inc. (Nasdaq: SQNM ), ... and Mr. David Pendarvis to its board of ... ,, Kenneth F. Buechler, Ph.D., was president, chief ... 1988 to 1994, Dr. Buechler was Biosite,s director ... was a senior research scientist for the diagnostics ...
Breaking Biology Technology:New Singapore-French nanotech lab opens at NTU 2New Singapore-French nanotech lab opens at NTU 3Hahnemann University Hospital Granted Magnet(R) Status 2Hahnemann University Hospital Granted Magnet(R) Status 3Indiana Industry, University and Community Leaders Capitalize on Next Generation of State's Life Sciences Growth 2Indiana Industry, University and Community Leaders Capitalize on Next Generation of State's Life Sciences Growth 3Indiana Industry, University and Community Leaders Capitalize on Next Generation of State's Life Sciences Growth 4Indiana Industry, University and Community Leaders Capitalize on Next Generation of State's Life Sciences Growth 5Sequenom Appoints Two New Board Members 2Sequenom Appoints Two New Board Members 3
... Sanofi-aventis,U.S. launched today a new 200 mg single-use ... patients who have,adjuvant stage III colon cancer and ... convenience, efficiency and safety in the,preparation of the ... 50 mg and 100 mg single- use vials. ...
... Pharsight,s Diabetes Meta-Database to Quantify Competitive Treatment Landscape and ... ... MOUNTAIN VIEW, Calif., Aug. 27 Pharsight,Corporation (OTC Bulletin ... optimizing clinical drug development, today,announced that it has licensed its ...
... (Nasdaq: ANDS ), a biopharmaceutical company committed ... the treatment of,hepatitis C virus (HCV) infection and ... promoted to the position of President and Chief,Executive ... to pursue,other opportunities. Dr. Worland has also been ...
Other Biology Technology:New 200 mg Vial for Eloxatin(R) (Oxaliplatin Injection) Offers Greater Convenience and Efficiency of Preparation 2New 200 mg Vial for Eloxatin(R) (Oxaliplatin Injection) Offers Greater Convenience and Efficiency of Preparation 3New 200 mg Vial for Eloxatin(R) (Oxaliplatin Injection) Offers Greater Convenience and Efficiency of Preparation 4New 200 mg Vial for Eloxatin(R) (Oxaliplatin Injection) Offers Greater Convenience and Efficiency of Preparation 5New 200 mg Vial for Eloxatin(R) (Oxaliplatin Injection) Offers Greater Convenience and Efficiency of Preparation 6New 200 mg Vial for Eloxatin(R) (Oxaliplatin Injection) Offers Greater Convenience and Efficiency of Preparation 7Pharsight Achieves First License Sale for Public-Source Database 2Pharsight Achieves First License Sale for Public-Source Database 3Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer 2Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer 3
(Date:12/16/2009)... Scientists in Scotland, Canada and the US have ... for whale conservation. The team,s findings, published in ... protected areas, identified through feeding behaviour, can benefit ... , "There are enormous challenges associated with setting ... as whales," said lead author Erin Ashe, a ...
(Date:12/16/2009)... Steven Chu announced today the winners of the 2009 ... and development supporting the Department of Energy and its ... a gold medal, a citation and $50,000. ... DC early next year., "The contributions made by these ... of the United States are wide-ranging and meaningful," Secretary ...
(Date:12/16/2009)... Our cells, molecules form an intricate network of ... to measure individual molecular reactions outside the cells. ... than in the laboratory, scientists suspect that the ... substantially from external probes. We expected the cellular ... Professor Dieter Braun. "However, our novel optical approach ...
Breaking Biology News(10 mins):Zoning the ocean may help endangered whales to recover 2Zoning the ocean may help endangered whales to recover 3Secretary Chu announces 2009 Ernest Orlando Lawrence Award winners 2Looking for the heartbeat of cellular networks 2Infinite Mind Announces the Launch of a New Online Vision Therapy Program eyeQ 6512 1Infinite Mind Announces the Launch of a New Online Vision Therapy Program eyeQ 6512 2CardioGenics Provides Update on Agreement with Merck Chimie for Its Silver Coated Paramagnetic Beads 6509 1CardioGenics Provides Update on Agreement with Merck Chimie for Its Silver Coated Paramagnetic Beads 6509 2CardioGenics Provides Update on Agreement with Merck Chimie for Its Silver Coated Paramagnetic Beads 6509 3Lotus Pharmaceuticals Inc to Exhibit at the 62nd PHARMCHINA 6506 1Lotus Pharmaceuticals Inc to Exhibit at the 62nd PHARMCHINA 6506 2
... botulism following cosmetic injections to the face indicates that ... resulted in toxin levels up to 40 times the ... the November 22/29 issue of JAMA. , Botulism ... of the spore-forming bacterium Clostridium botulinum and toxin-producing strains ...
... further than the air around you. It could be ... to a first-of-its-kind census of airborne microbes recently conducted ... Berkeley National Laboratory (Berkeley Lab). , The team ... in air samples taken from the Texas cities of ...
... conditions in flea carriers and mammal hosts, Pacific ... and likely proteins in the plague-bacterium Yersinia ... the disease’s virulence. , The team, led by ... Lipton and Kim Hixson, identified the proteins as ...
Other Biology News:Highly concentrated botulinum preparation for cosmetic injections can result in severe illness 2Highly concentrated botulinum preparation for cosmetic injections can result in severe illness 3Study finds the air rich with bacteria 2Study finds the air rich with bacteria 3Study finds the air rich with bacteria 4Plague proteome reveals proteins linked to infection 2
... ProteinChip arrays have been developed for ... samples. A variety of ProteinChip chemical ... according to their unique biochemical properties. ... allowing side-by-side sample comparison, and the ...
... VersArray ChipWriter Pro systems are ... proteins, or other biological samples. VersArray ... for uniformity, spot density, and reproducibility ... a variety of substrates. Their modular ...
... Ciphergen's ProteinChip arrays have been ... from biological samples. A variety of ... of proteins according to their unique ... different spots, allowing side-by-side sample comparison, ...
... ProteinChip arrays have been developed for ... samples. A variety of ProteinChip chemical ... according to their unique biochemical properties. ... allowing side-by-side sample comparison, and the ...
Biology Products: